Vertex Pharma (NASDAQ:VRTX) has bounced again on Tuesday after Morgan Stanley upgraded the commercial-stage biotech citing a good setup following a setback to AbbVie’s (ABBV) plans to problem its dominance in cystic fibrosis.
Vertex (VRTX) crashed on Monday after saying that the U.S. Meals and Drug Administration (FDA) imposed a scientific maintain on its stem cell-derived diabetes candidate, VX-880.
In a analysis be aware issued on Tuesday, Morgan Stanley analysts Matthew Harrison and Charlie Yang upgraded the inventory to Equal Weight from Underweight, citing a extra favorable risk-reward setup. The worth goal of $250 per share implies a draw back of ~5% draw back to the final shut.
The analysts estimate that the corporate’s cystic fibrosis enterprise is price $200 per share, and argue that given the present market circumstances, the traders are prepared “to pay a premium for draw back safety from the long-term readability on CF cashflows.”
Given its ambitions in cystic fibrosis, AbbVie (ABBV) may very well be a risk to Vertex (VRTX) with a detrimental risk-reward, the duo had beforehand assumed. Nevertheless, “the chance/reward is skewed extra favorably put up AbbVie failure,” they famous.
On the current earnings name, AbbVie’s (ABBV) Chief Scientific Officer Tom Hudson stated that its triple mixture remedy for CF didn’t carry out as anticipated to help additional improvement. Nevertheless, the corporate hasn’t dropped its plans in CF, with a Part 2 trial anticipated to start early subsequent 12 months concentrating on a brand new triple mixture remedy.